@masterthesis{Bravin, type = {Bachelor Thesis}, author = {Bravin, Luca}, title = {Nanoprobe-based immuno-LAMP for Whole-pot Nucleic Acid-Antigen co-detection}, school = {Hochschule Rhein-Waal}, abstract = {Point-of-Care testing (POCT) is a novel approach that aims to fill in the gaps by bringing state-of-art technologies to the field outside of the clinics. Several aspects of these novel technologies are currently challenging their real-world application as their use is often limited to centralized locations. Nevertheless, novel engineering approaches coupled with the current technological development are now working towards new platforms that could potentially serve to deliver these technologies at a decentralized level. Microfluidic platforms, LFAs, DNA microarrays and others are novel tools that are being explored for their potential impact in the development of Point-of-care (POC) technologies. These platforms altogether allow for the processing of a very small amount of sample in a semi-automated, miniaturized, portable device that requires little to no training from the user side. Furthermore, they allow to reach clinically-relevant results within the same device in a short amount of time without the need for logistic or time resources. Nevertheless, the sensitivity and accuracy offered by these methods is often of a lower degree when compared to standard laboratory tests. Therefore, new approaches are being explored which involve the integration of cutting-edge nanotechnology to POCT. In this project, the proof of concept of an assay for the dual detection of nucleic acid and protein biomarker was attempted using a DNA amplification technique also called, commonly referred to as immuno-PCR (iPCR). Although PCR is the most known and developed assay, this assay was designed to work with the LAMP assay. This novel technique allows the isothermal amplification of nucleic acid within a relative short incubation time thus making this a perfect candidate for a potential POC platform to be used in RLS. Furthermore, the use of different nanoprobes in the assay enabled the improvement of several aspects of the test which allows to achieve similar results to the current standard methods. Several constraints related to the use of this novel technology challenge the application of such tests field. Nevertheless, the integration of this test in a microarray platform could overcome these limitations, offering a platform that could potentially detect multiple diseases within the same test on a LOC format. Although iLAMP platform remains a promising alternative for the development of next-generation nucleic acid-based POCT, further research will be needed to assess the performance of this assay with clinical samples and determine the feasibility of DNA microarray-based detection}, language = {en} }